Selpercatinib selectively inhibits activated RET, thereby inhibiting tumor growth, and it has demonstrated high efficacy and safety in patients with RET mutation-positive MTC in the LIBRETTO-001 trial [15]. Here, RET is linked to medullary thyroid gland carcinoma.